New combo targets hard-to-treat lung cancer in early trial
NCT ID NCT06249282
First seen Apr 04, 2026 · Last updated May 21, 2026 · Updated 7 times
Summary
This early-phase study tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 15 adults who have already tried a KRAS inhibitor will receive the combination. The main goal is to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope at Irvine Lennar
RECRUITINGIrvine, California, 92618, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.